S.Amdt. 1024
What it does: Adds SEC. __. PROHIBITION OF REORGANIZATION PLAN PENDING REVIEW wherever appropriate
Sen. Ken Salazar (D-CO)What it changes
1 change to S. 1082
Adds SEC. __. PROHIBITION OF REORGANIZATION PLAN PENDING REVIEW wherever appropriate
Adds a sectionInserted: SEC. __. PROHIBITION OF REORGANIZATION PLAN PENDING REVIEW.
Inserted: (a) In General.--The Commissioner of Food and Drugs may not implement a reorganization plan that reduces or consolidates the number of laboratory facilities currently in operation within the Office of Regulatory Affairs of the Food and Drug Administration pending a comprehensive review of the reorganization plan by the Comptroller General of the United States to determine--
Inserted: (1) the impact of the reorganization on the mission of the Food and Drug Administration to ensure that foods, cosmetics, and medical products are safe, effective, and properly promoted and labeled;
Inserted: (2) the projected cost savings; and
Inserted: (3) the projected operational efficiencies.
Inserted: (b) Report.--Not later than 1 year after the date of enactment of this section, the Comptroller General of the United States shall issue a report on the impact of the reorganization plan described in subsection (a).
The amendment doesn't say where this goes; the clerk decides.
Original wording
At the appropriate place, insert the following:
Read automatically from the Congressional Record. Check the original before relying on it.
As printed
SA 1024. Mr. SALAZAR submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:
At the appropriate place, insert the following:
SEC. __. PROHIBITION OF REORGANIZATION PLAN PENDING REVIEW.
(a) In General.--The Commissioner of Food and Drugs may not implement a reorganization plan that reduces or consolidates the number of laboratory facilities currently in operation within the Office of Regulatory Affairs of the Food and Drug Administration pending a comprehensive review of the reorganization plan by the Comptroller General of the United States to determine--
(1) the impact of the reorganization on the mission of the Food and Drug Administration to ensure that foods, cosmetics, and medical products are safe, effective, and properly promoted and labeled;
(2) the projected cost savings; and
(3) the projected operational efficiencies.
(b) Report.--Not later than 1 year after the date of enactment of this section, the Comptroller General of the United States shall issue a report on the impact of the reorganization plan described in subsection (a).
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Senate amendment submitted
May 2, 2007